Physician profile
Michael B Brenner
NPI 1699732909
$114,972.33
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $9,558 · 2021: $9,710 · 2022: $275 · 2023: $15K · 2024: $55K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $63K · Travel and Lodging: $5,747 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,050 · Food and Beverage: $897.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $62,511.00 |
| Travel and Lodging | $5,746.60 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,050.00 |
| Food and Beverage | $896.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $71,617.97 | 2019-2024 | |
| Abbvie INC. | $20,599.59 | 2021-2024 | |
| Modernatx, INC. | $8,926.00 | 2024 | |
| Janssen Research & Development, LLC | $4,860.00 | 2024 | |
| Pfizer INC. | $2,643.77 | 2019-2024 | |
| Otsuka Pharmaceutical Co., Ltd. | $2,500.00 | 2024 | |
| Alexion Pharmaceuticals, INC. | $1,800.00 | 2024 | |
| Ucb Sa | $1,500.00 | 2024 | |
| Chugai Pharmaceutical Co., Ltd. | $525.00 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Brenner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.